Shreyas Joshi

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 20, 2025Author(s):,Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 20, 2025Author(s):,Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting promising response rates but significant toxicity concerns that currently limit widespread adoption to select high-risk patients, pending further trial data and safety protocol development.

2 weeks ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 13, 2025Author(s):,Panelists discuss current FDA-approved treatments for BCG-unresponsive carcinoma in situ, noting varying response rates among pembrolizumab, nadofaragene, and BCG combined with IL-15 superagonist, while highlighting promising investigational combination immunotherapies like oncolytic viruses and checkpoint inhibitors that may improve outcomes in this challenging patient population.

2 weeks ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 13, 2025Author(s):,Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in oncologic outcomes and quality of life, and emphasizing the need for shared decision-making as prospective studies like CISTO refine patient selection for personalized treatment strategies.

4 weeks ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

Author(s):,Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care. The current standard of care for non–muscle-invasive bladder cancer (NMIBC) is highly dependent on risk stratification.